Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

PI3K inhibitors for R/R CLL

August 31st 2021

An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

CLL: Venetoclax in the R/R Setting

August 31st 2021

Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.

Emerging Strategies in the Management of Relapsed/Refractory CLL

August 30th 2021

Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.

Therapeutic Sequencing Strategies in Relapsed/Refractory CLL

August 30th 2021

Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.

Key Clinical Data in Relapsed/Refractory CLL

August 30th 2021

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

High-Risk Patients With R/R CLL

August 24th 2021

A discussion about treatment for high-risk patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

CLL: BTK Inhibitors in the R/R Setting

August 24th 2021

Nicole Lamanna, MD, provides an overview of Bruton's tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in the relapsed/refractory (R/R) setting.

Frontline Therapy for CLL: Emerging Agents and Approaches

August 23rd 2021

Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.

Which Path to Take in Frontline Therapy for CLL?

August 23rd 2021

Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.

Looking Toward the Future of CLL Management

August 23rd 2021

An expert hematologist/oncologist highlights key takeaways for the future management of chronic lymphocytic leukemia given an evolving therapeutic landscape.

Optimal Treatment Strategies for Chronic Lymphocytic Leukemia

August 23rd 2021

Practical advice on optimal toxicity management and sequencing of therapy in patients with chronic lymphocytic leukemia.

Acalabrutinib vs Ibrutinib: Head-to-Head Data in Previously Treated CLL

August 23rd 2021

Tara Graff, DO, MS, reflects on the head-to-head comparison data of acalabrutinib vs ibrutinib in patients with previously treated CLL.

Frontline BTKi Therapy in CLL: The ELEVATE-TN Study 4-Year Follow-up

August 23rd 2021

Expert insight on the use of frontline BTK inhibitor monotherapy over combination therapy in CLL regarding the ELEVATE-TN trial’s readout.

Rationale and Use of BTK Inhibitors as Initial Treatment for CLL

August 23rd 2021

A comprehensive breakdown of the rationale behind targeting BTK signaling in CLL, as well as considerations for clinical experience with the available BTK inhibitors.

The Evolution of CLL Treatment

August 23rd 2021

Tara Graff, DO, MS, outlines the current treatment paradigm for chronic lymphocytic leukemia by discussing the use of novel agents, molecular testing, and risk stratification.

Long-term Follow-up Solidifies Role of Fixed-duration Venetoclax Plus Rituximab in Relapsed/Refractory CLL

August 17th 2021

Updated efficacy outcomes of the phase 3 MURANO trial demonstrated that fixed-duration venetoclax plus rituximab is an effective treatment approach for patients with relapsed/refractory chronic lymphocytic leukemia and did not compromise response to subsequent therapy or overall survival.

CLL: GLOW Trial Overview

August 17th 2021

Steven Coutre, MD, provides an overview of the phase 3 GLOW trial, as well as other novel and emerging combinations for the treatment of chronic lymphocytic leukemia (CLL).

CLL Therapies: Novel Combinations

August 17th 2021

John Allen, MD, provides an overview of data looking at emerging combinations as initial therapy for chronic lymphocytic leukemia (CLL).

Frontline Targeted Therapy in CLL: Tolerability and Toxicity Management

August 16th 2021

A comprehensive breakdown of the tolerability of frontline targeted therapies used to manage chronic lymphocytic leukemia and toxicity management.

Moving the Dial on CLL Management: Sequencing Strategies and Unmet Needs

August 16th 2021

Before addressing unmet needs in the management of CLL, Brad S. Kahl, MD, outlines optimal sequencing strategies in the current treatment paradigm.